Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 7:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 216 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: sertraline (Zoloft) Clear all
Completed Phase 3 Interventional Results available

Treatment of Obsessive Compulsive Disorder in Children

NCT00074815
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Serotonin reuptake inhibitors management, Cognitive behavioral therapy by a psychologist, Instructional cognitive behavioral therapy by a psychiatrist
Drug · Behavioral
Lead sponsor
Duke University
Other
Eligibility
7 Years to 17 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
3
States / cities
Durham, North Carolina • Philadelphia, Pennsylvania • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 29, 2014 · Synced Oct 6, 2026, 7:06 PM EDT
Completed Phase 4 Interventional Results available

Frontal Hypoperfusion Effects on Antidepressant Outcomes in Late-Life Depression

NCT01896934
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Sertraline
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
60 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 6, 2026, 7:06 PM EDT
Completed Phase 3 Interventional Results available

Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD

NCT04124614
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Brexpiprazole, Sertraline, Placebo
Drug · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 6, 2026, 7:06 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

NCT01436149
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SPD489 (Lisdexamfetamine dimesylate ), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
47
States / cities
Birmingham, Alabama • Carson, California • Irvine, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 6, 2026, 7:06 PM EDT
Completed Phase 4 Interventional Results available

Treatments for Psychogenic Nonepileptic Seizures (NES)

NCT00159965
View directory record Official record
Conditions
Convulsion, Non-Epileptic, Conversion Disorder, Depression, Stress Disorders, Post-Traumatic
Interventions
sertraline, placebo
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 95 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Oct 6, 2026, 7:06 PM EDT
Completed Phase 4 Interventional

A Study of Sertraline and Early Alprazolam XR Administration Versus Sertraline Only in Panic Disorder Patients

NCT00198094
View directory record Official record
Conditions
Panic Disorder
Interventions
Sertraline and Alprazolam XR
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
3
States / cities
Tampa, Florida • Indianapolis, Indiana • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 22, 2007 · Synced Oct 6, 2026, 7:06 PM EDT
Completed Phase 2Phase 3 Interventional

Risperidone Augmentation for PTSD

NCT00215241
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
sertraline and risperidone
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Atlanta, Georgia • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Oct 6, 2026, 7:06 PM EDT
Completed Phase 2 Interventional

Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline)

NCT00000451
View directory record Official record
Conditions
Alcoholism, Alcohol Dependence
Interventions
sertraline, naltrexone
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 29, 2013 · Synced Oct 6, 2026, 7:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Magnetic Resonance Imaging Study of Geriatric Depression

NCT00245557
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Sertraline
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
55 Years to 89 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Oct 6, 2026, 7:06 PM EDT
Completed Phase 2 Interventional Results available

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

NCT03321526
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
JNJ-42847922, Placebo Matching to JNJ-42847922, Quetiapine XR, Placebo Matching to Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Phoenix, Arizona • Tempe, Arizona • Rogers, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 6, 2026, 7:06 PM EDT
Terminated Phase 2 Interventional

Multicentre Trial to Evaluate the Safety and Efficacy of CP-316,311 in Major Depressive Disorder

NCT00143091
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
CP-316,311, Placebo, Sertraline
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Bellevue, Washington • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 24, 2008 · Synced Oct 6, 2026, 7:06 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Sertraline for the Prevention of Recurrent Postpartum Depression

NCT00276900
View directory record Official record
Conditions
Depression
Interventions
Sertraline
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 7, 2013 · Synced Oct 6, 2026, 7:06 PM EDT
Completed Phase 4 Interventional

SMART Trial to Predict Anhedonia Response to Antidepressant Treatment

NCT05537584
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Sertraline, Bupropion
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 6, 2026, 7:06 PM EDT
Completed No phase listed Observational

Treatment Outcome of Vascular Depression

NCT00045773
View directory record Official record
Conditions
Depressive Disorder, Depression
Interventions
Sertraline
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
60 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
2
States / cities
St Louis, Missouri • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 31, 2017 · Synced Oct 6, 2026, 7:06 PM EDT
Completed No phase listed Observational Results available

Sertraline Pediatric Registry for the Evaluation of Safety (SPRITES)

NCT01302080
View directory record Official record
Conditions
Obsessive Compulsive Disorder
Interventions
sertraline, psychotherapy
Drug · Behavioral
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
6 Years to 16 Years
Enrollment
941 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
44
States / cities
Dothan, Alabama • Imperial, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 6, 2026, 7:06 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder

NCT01254305
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Levomilnacipran ER, Paroxetine, Sertraline, Citalopram or Fluoxetine., Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
20
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Cerritos, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Oct 6, 2026, 7:06 PM EDT
Completed Phase 4 Interventional

Treatment Trial for Psychogenic Nonepileptic Seizures

NCT00835627
View directory record Official record
Conditions
Convulsion, Non-Epileptic, Conversion Disorder, Depression, Stress Disorders, Post-Traumatic, Dissociative Disorders
Interventions
sertraline, CBT-ip, Combined (sertraline + CBT-ip), Standard Care
Drug · Behavioral · Other
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 95 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Stanford, California • Cincinnati, Ohio • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 10, 2014 · Synced Oct 6, 2026, 7:06 PM EDT
Completed Not applicable Interventional Results available

Study Comparing 3 Different Treatments for Arthritis of the Lower Back (Lumbar Spinal Stenosis)

NCT01943435
View directory record Official record
Conditions
Lumbar Spinal Stenosis
Interventions
NSAIDs; adjunctive analgesics; adjunctive anti-depressants, Lumbar epidural injection, Joint Mobilizations (spine, sacroiliac, hip), Individualized exercises: clinical setting, Group Exercise: community setting
Drug · Procedure · Other
Lead sponsor
Michael Schneider, DC, PhD
Other
Eligibility
60 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Oct 6, 2026, 7:06 PM EDT
Completed Phase 2Phase 3 Interventional

Treatment of Adolescent Suicide Attempters (TASA)

NCT00080158
View directory record Official record
Conditions
Depression, Suicide, Attempted
Interventions
fluoxetine, sertraline, citalopram, escitalopram, bupropion, mirtazapine, venlafaxine, lithium, Cognitive Behavioral Therapy
Drug · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
12 Years to 18 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
6
States / cities
Baltimore, Maryland • New York, New York • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Oct 6, 2026, 7:06 PM EDT
Completed No phase listed Observational

Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

NCT00667121
View directory record Official record
Conditions
Breast Cancer, Depression, Hot Flashes, Psychosocial Effects of Cancer and Its Treatment
Interventions
citalopram hydrobromide, escitalopram oxalate, gabapentin, sertraline hydrochloride, tamoxifen citrate, venlafaxine, molecular genetic technique, high performance liquid chromatography, laboratory biomarker analysis, pharmacological study, adjuvant therapy
Drug · Genetic · Other + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 6, 2026, 7:06 PM EDT
Completed Phase 1 Interventional

Multiple Ascending Dose Phase 1 Study of ALA-3000

NCT06965569
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
ALA-3000, Placebo, escitalopram, sertraline, duloxetine or venlafaxine XR
Drug
Lead sponsor
Alar Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
4
States / cities
Little Rock, Arkansas • St Louis, Missouri • Eatontown, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 6, 2026, 7:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identifying Brain and Genetic Markers of Sertraline Treatment Response in People With Social Anxiety Disorder

NCT00872131
View directory record Official record
Conditions
Anxiety Disorders
Interventions
Sertraline
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 55 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 23, 2011 · Synced Oct 6, 2026, 7:06 PM EDT
Completed Not applicable Interventional Results available

Early Detection and Intervention for the Prevention of Psychosis

NCT00531518
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Depression, Psychotic Disorders
Interventions
aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine, Psychoeducational multifamily group treatment, Supported employment and education
Drug · Behavioral
Lead sponsor
MaineHealth
Other
Eligibility
12 Years to 25 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
6
States / cities
Sacramento, California • Portland, Maine • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2016 · Synced Oct 6, 2026, 7:06 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02417064
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
37
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Garden Grove, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 6, 2026, 7:06 PM EDT